LAWRENCE E. BRODER, M.D.; STEPHEN K. CARTER, M.D.
The clinical features of 52 patients with metastatic pancreatic islet cell carcinoma treated with streptozotocin (NSC-85998) were analyzed. Seventy-nine percent of the patients had functioning tumors, with the majority secreting insulin; 21% of the patients had nonfunctioning tumors. The tumors were found primarily in the tail of the pancreas and were noted with equal frequency in men and women, at a median age of 52 years. Metastases were mainly to the liver and by local extension; distant metastases were rarely noted. The most frequently reported presenting symptom was hypoglycemia, occurring in 90% of the functioning-tumor patients. Gastrointestinal ulceration and diarrhea were less frequently observed. An overall median survival of 908 days, from diagnosis to last follow-up, was noted. There was no significant difference in survival rates between the sexes or between the functioning- as compared to the nonfunctioning-tumor patients.
BRODER LE, CARTER SK. Pancreatic Islet Cell Carcinoma: I. Clinical Features of 52 Patients. Ann Intern Med. ;79:101–107. doi: 10.7326/0003-4819-79-1-101
Download citation file:
Published: Ann Intern Med. 1973;79(1):101-107.
Gastroenterology/Hepatology, Hematology/Oncology, Pancreatic Disease.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use